Guardant Brings Home Strong Results as Liquid Biopsy Space Heats Up

Guardant Health is one of the biggest names in liquid biopsy and after Monday its presence in the space can only increase. The Redwood City, CA-based company revealed results of a study conducted by it along with researchers from The University of Texas MD Anderson Cancer Center, the Samsung Medical Center, and other institutions. Results show the Guardant360 assay can accurately detect microsatellite instability status (MSI) as accurately as tissue biopsy. The company said this is the largest comparison of MSI testing to traditional tissue methods across multiple solid tumor types. Findings were reported in Clinical Cancer Research. For advanced cancer patients, MSI is a good predictor of response to immunotherapy with PD-1 and PD-L1 inhibitors in multiple tumor types. It has been reported to occur in about 1% of cases, and any patient with advanced cancer who is found to be MSI-High is eligible for treatment with immunotherapy. MSI-High occurs most frequently in colorectal, endometrial, and gastroesophageal cancers. To validate Guardant360’s MSI detection, researchers compared the results of 1,145 Guardant360 samples to MSI status determined using standard-of-care tissue testing results taken from medical records. The results from Guardant360 were the same as the standard-of-care tissue test in 98.4% of cases. Additionally, it is the first report of immune checkpoint inhibitor therapy outcomes in plasma MSI-High patients. In a cohort of 16 MSI-...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news